Table 4

Incidence of neutropenia during administration of study drug and during the 100-day posttransplantation period

Patient absolute neutrophil levels, no. (%)Placebo, n = 28Maribavir dose groups
100 mg twice daily, n = 28400 mg once daily, n = 28400 mg twice daily, n = 26*
While taking study drug     
    Less than 1000/mm3 4 (14) 6 (21) 5 (18) 4 (15) 
    Less than 750/mm3 4 (14) 4 (14) 3 (11) 3 (12) 
    Less than 500/mm3 2 (7) 3 (11) 2 (7) 1 (4) 
During the 100-day posttransplantation period     
    Less than 1000/mm3 11 (39) 7 (25) 6 (21) 9 (35) 
    Less than 750/mm3 11 (39) 4 (14) 5 (18) 7 (27) 
    Less than 500/mm3 6 (21) 3 (11) 3 (11) 3 (12) 
Patient absolute neutrophil levels, no. (%)Placebo, n = 28Maribavir dose groups
100 mg twice daily, n = 28400 mg once daily, n = 28400 mg twice daily, n = 26*
While taking study drug     
    Less than 1000/mm3 4 (14) 6 (21) 5 (18) 4 (15) 
    Less than 750/mm3 4 (14) 4 (14) 3 (11) 3 (12) 
    Less than 500/mm3 2 (7) 3 (11) 2 (7) 1 (4) 
During the 100-day posttransplantation period     
    Less than 1000/mm3 11 (39) 7 (25) 6 (21) 9 (35) 
    Less than 750/mm3 11 (39) 4 (14) 5 (18) 7 (27) 
    Less than 500/mm3 6 (21) 3 (11) 3 (11) 3 (12) 
*

One patient randomized to maribavir 400 mg twice daily did not receive study drug and was excluded from the analysis.

or Create an Account

Close Modal
Close Modal